Association between COMT Val158Met and DAT1 polymorphisms and depressive symptoms in the obese population

Maciej Bielinski¹  
Marcin Jaracz¹  
Natalia Lesiewska¹  
Marta Tomaszewska¹  
Marcin Sikora²  
Roman Junik³  
Anna Kamińska³  
Andrzej Tretyn²  
Alina Borkowska¹  

¹Department of Clinical Neuropsychology, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Bydgoszcz, ²Department of Biotechnology, Nicolaus Copernicus University in Toruń, Toruń, ³Department of Endocrinology and Diabetology, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland

Objectives: Depressive symptoms are common among patients with obesity. Abnormalities in dopamine signaling involved in the reward circuit may ensue excessive consumption of food, resulting in obesity and leading to neuropsychiatric disorders such as depression. This study sought to investigate the association of polymorphisms in the genes encoding DAT1/SLC6A3 and COMT with the intensity of depressive symptoms in obese subjects.

Participants and methods: Prevalence and severity of depressive symptoms were assessed in a group of 364 obese patients using the Beck Depression Inventory (BDI) and the Hamilton Depression Rating Scale (HDRS). Genetic polymorphisms in DAT1 and COMT were evaluated in peripheral blood samples.

Results: The results indicated an association between DAT1 alleles and depressive symptoms, as well as severity of obesity. Subjects homozygous for the nine-repeat allele scored higher in BDI (P=0.022) and HDRS (P=0.00001), suggesting higher intensity of depression in both sexes. This allele was also associated with the highest body mass index (BMI; P=0.001). Carriers of the Val158Met allele of COMT scored higher on both depression scales (BDI, P=0.0005; HRDS, P=0.002) and had the highest BMI values.

Conclusion: Polymorphisms in the DAT1 and COMT genes are associated with a greater intensity of depressive symptoms in the obese population.

Keywords: dopaminergic signaling, obesity, depressive symptoms, reward circuit, gene polymorphism

Introduction

In recent decades, obesity has become a serious health problem worldwide. In 2014, nearly 2 billion people were overweight and >600 million were obese.¹ High body weight is a risk factor for depressive symptoms,² which are also considered to be disabling conditions with very high prevalence.³,⁴ Both depression and obesity are associated with elevated mortality and reduced quality of life; accordingly, their prevention and treatment are important priorities in many industrialized nations.⁵,⁶ For obesity, however, interventions seldom result in lasting weight loss and often fail to prevent future obesity.⁷ Likewise, for depressive disorders, more effective therapeutic approaches and novel treatment strategies are urgently required.⁸ A better understanding of the processes that account for the weight gain and elevated morbidity associated with depression would facilitate development of more efficient preventive and therapeutic interventions.

Dopamine signaling is closely connected with emotional and motivational functioning, especially in relation to reward-seeking behaviors such as drug abuse or...
neurotransmission is terminated. The terminals. Therefore, the dopaminergic activity in synaptic areas are presumed to be responsible for susceptibility to and the development of obesity and depressive disorders.8,10–12

Recent data show that the dysfunction in dopaminergic circuits may be responsible for the pathogenesis of mood disorders. Likewise, growing evidence describe the role of NAc in the regulation of traits that meditate behavioral abnormalities connected with depression.11 Grace suggested that diminished activation within subcortical circuits following their hyperactivity may result in anhedonia and depression. The abovementioned symptoms might be caused by the compensatory downregulation of dopamine neurons due to acute dopamine system activity.13

Many genetic studies provide evidence that genes involved in dopaminergic neurotransmission contribute to personality traits and major mental illnesses.10,14–18 Gatt et al10 implicated DAT1 in depression. Moreover, Massat et al19 linked the COMT Val158Met polymorphism to early onset of depressive disorders. The influence of COMT genotype on amygdale is not as clear as its impact on PFC. However, it is speculated that alterations in the activation within this areas, which are rendered by COMT polymorphism, may result in a vulnerability to affective disorders.18 Several studies also tested the association between obesity and genotype distributions of allele frequencies.20–22 Thaler et al21 found that homozygosity for the DAT1 ten-repeat allele determines the risk for eating-related symptomatology, whereas Sikora et al21 revealed that homozygosity for the nine-repeat allele was associated with a higher body mass index (BMI) in a group of 506 women. Other studies have reached conflicting conclusions.21,24,25 For example, Uzun et al24 excluded the link of the DAT1 gene to BMI and obesity and Thaler et al21 did not detect an association between COMT genotypes and alterations in BMI.

The human dopamine active transporter (DAT) regulates dopamine concentration in the synaptic cleft between dopamine neurons and is mostly distributed in the basal ganglia of the human brain.26 The role of this specific protein is to reuptake the dopamine that is released into presynaptic terminals. Therefore, the dopaminergic activity in synaptic neurotransmission is terminated. The DAT1 gene, also called SLC6A3, is localized to chromosome 5p15.3 and has a 40-bp variable number tandem repeat (VNTR) polymorphism within its 3′ untranslated region. The two most common alleles have nine and ten repeats, respectively. The A9 allele is putatively associated with higher levels of dopamine in the striatum and is more frequent among those who are addicted to psychoactive substances.27,28 In some studies, homozygosity of the nine-repeat allele (DAT-S) has been linked to reduced transporter protein expression, leading to a higher dopamine availability in the synapse29 and an elevated ventral striatal reactivity.30,31 On the contrary, homozygosity of the ten-repeat allele (DAT-L) is responsible for higher overall DAT concentration, which correlates with dopamine (DA) reuptake, and is thus associated with reduced synaptic dopamine availability.32 However, exact effects on DAT expression is still unclear due to evidence describing converse results in regard to aforementioned DAT1 SLC6A3 polymorphism and DA concentration.33,34

COMT is the enzyme that regulates dopamine catabolism. It is translated at higher levels in the PFC and temporal areas than in subcortical regions like striatum.18,35 COMT degrades DA and inhibits the biological function of this neurotransmitter after it is released in the synaptic cleft. COMT occurs in two isoforms, cell membrane bound (M-COMT) and soluble (S-COMT), which are encoded by the same gene (COMT). S-COMT consists of 221 amino acids, and M-COMT has 51 additional amino acids.36 S-COMT predominates outside the brain, whereas M-COMT is more abundant in the brain and is thus implicated in central dopaminergic activity. The COMT gene is located at 22q11.2 chromosome, and the common polymorphism is the Val158Met substitution that alters the activity of the encoded enzyme and may have neurobiological consequences.37 Three different genotypes of the COMT Val158Met polymorphism exist: Met/Met, Met/Val, and Val/Val. Individuals homozygous for the Met allele have lower COMT activity and degrade extrasynaptic dopamine more slowly, resulting in higher DA availability in the PFC, than COMT Val/Val subjects who have higher COMT activity leading to reduced dopaminergic signaling.38,39

Studies to date have yielded inconsistent results regarding the relationship of dopaminergic activity to obesity and depressive disorders. Accordingly, in this study, we sought to investigate the association of DAT1 and COMT polymorphisms with the intensity of depressive symptoms in the big sample of obese participants. There will be attempts to elucidate which mechanisms within the reward circuits are responsible for abovementioned connections.
Participants and methods

Participants

A total of 364 Caucasian patients of Polish nationality were enrolled in the study. Individuals included in the study were recruited from patients treated for obesity in health clinic. Demographic characteristics including age and sex of the subjects were collected (Table 1). The mean age of participants was 52 years (range, 39–69 years) for women and 56 years (range, 42–67 years) for men. Subjects with a severe somatic or psychiatric disorder per Diagnostic and Statistical Manual of Mental Disorders, 4th edition; any neurological abnormality; or any addiction to illicit drugs or alcohol were excluded from the study. Participants were informed about the aims of this study and provided written informed consent. Permission for the study was obtained from the Bioethical Commission of the Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz (No 533/2008).

Clinical assessments and measures

Clinical evaluation was based on physical examination and medical history. Emphasis was placed on facets that influence weight gain or that are associated with psychological disorders, such as biometric analyses and concomitant diseases, eg, hypertension, hypercholesterolemia, and diabetes mellitus.

Biometric analyses were performed to measure weight (kg), height (m), and BMI. As a proxy for adiposity, BMI was calculated as the ratio between weight (kg) and squared height (m²). Primary obesity was defined as a BMI of >30. Secondary causes of obesity were excluded based on medical history, physical examination, and biochemical results (eg, cortisol, prolactin, and thyroid-stimulating hormone levels).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Females (n=231)</th>
<th>Males (n=133)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>52.0 (39.0–69.0)</td>
<td>56.0 (42–67)</td>
<td>0.6</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.63 (1.6–1.69)</td>
<td>1.74 (1.7–1.76)</td>
<td><strong>0.000001</strong></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>97 (81–115)</td>
<td>102 (90–130)</td>
<td><strong>0.000006</strong></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>37.2 (32.4–46.8)</td>
<td>35.2 (30.8–43.9)</td>
<td><strong>0.008</strong></td>
</tr>
<tr>
<td>I (BMI 30–34.9)</td>
<td>n=96</td>
<td>n=64</td>
<td></td>
</tr>
<tr>
<td>II (BMI 35–39.9)</td>
<td>n=20</td>
<td>n=42</td>
<td></td>
</tr>
<tr>
<td>III (BMI &gt;40)</td>
<td>n=49</td>
<td>n=93</td>
<td></td>
</tr>
<tr>
<td>BDI</td>
<td>9 (5–17.0)</td>
<td>11 (6–18)</td>
<td>0.16†</td>
</tr>
<tr>
<td>HDRS</td>
<td>3.0 (2.0–11.0)</td>
<td>9 (2–14)</td>
<td><strong>0.001</strong></td>
</tr>
</tbody>
</table>

Notes: Values are expressed as the median (25%–75%) or as number of patients (n). Significance of differences between sexes was determined by the Mann–Whitney U test. Bold values indicate statistical significance. *Though BDI values are not statistically significant, there is a trend to significance.

Abbreviations: BMI, body mass index; BDI, Beck Depression Inventory; HDRS, Hamilton Depression Rating Scale.

Key emotional depressive symptoms and their severity were measured using the Beck Depression Inventory (BDI; an assessment of subjective depression) and Hamilton Depression Rating Scale (HDRS; an assessment of objective depression). Depression was defined based on an established cutoff score for the Polish population: ie, BDI score >12 and HDRS score >7.

Genotyping

Genomic DNA was extracted from 7 to 10 mL of peripheral blood using the method of Lahiri and Schnabel. Blood was collected and mixed with 0.5 mL of 0.5 M EDTA, frozen in liquid nitrogen, and stored at −80°C prior to extraction. DAT1 and COMT genotypes were determined by polymerase chain reaction (PCR). The following primers were used: DAT1 forward, 5′-TGTGGTGTTAGGAACGCTCTAG-3′; DAT1 reverse, 5′-CTCTCTGGAGGTACGGCTCAAGG-3′; COMT forward, 5′-AGCTCCAAGCGGCTCAACAG-3′; and COMT reverse, 5′-CAAAGTGGCATGCCCTCCC-3′.

PCR products were then separated by agarose gel electrophoresis using O’RangeRuler™ 50 bp DNA Ladder (Fermentas) as a length marker (Figures 1 and 2).

Statistical analysis

The Shapiro–Wilk test was initially used to assess the normality of the distribution of study variables. Because the distribution was non-normal, nonparametric tests were used in subsequent analysis. Statistical significance of differences was calculated using the Mann–Whitney U test, and for comparisons with three or more groups, the Kruskal–Wallis analysis of variance (ANOVA) was applied. The NIR Fisher
test was used for post hoc analyses. Analysis of covariance (ANCOVA) was performed to examine interaction effects. Statistica 10.0 was used for statistical analyses, and the computer program “Utility Programs for Analysis of Genetic Linkage” (Copyright © 1988 J. Tot) was utilized to test for goodness of fit to the Hardy–Weinberg equilibrium.

Results

The first analysis sought to determine whether any significant demographic, psychological, or clinical differences were present between women and men (Table 1). Female participants scored significantly higher in BMI than males, whereas males presented with more severe depressive symptoms, as assessed by HDRS ($P=0.001$) and BDI ($P=0.16$), although the BDI results were not statistically significant. For information, there are also given numbers of individuals with particular degree of obesity.

We calculated the R-Spearman rank correlations for depressive scores and found positive significant correlations between BDI and HDRS values ($r=0.84; P=0.000002$). In addition, HDRS and BMI were significantly positively correlated ($r=0.22; P=0.00002$), but the positive correlation between BDI and BMI was not significant.

Next, we examined the relationship of $DAT1$ alleles to the intensity of depression symptoms and calculated BMI (Table 2). The results revealed an association between $DAT1$ genotypes and both depressive symptoms as well as severity of obesity. Homozygotes for the nine-repeat allele scored higher in BDI and HDRS, suggesting a greater intensity of depression, in both sexes. This allele was also associated with the highest BMI, suggesting that such patients are at a greater risk of obesity. The population was in Hardy–Weinberg equilibrium ($P=0.1364$).

A similar analysis was performed for $COMT$ gene polymorphisms (Table 3). The data show the distribution of $COMT$ genotypes (ie, Met/Met, Met/Val, and Val/Val). Met/Met carriers had the highest scores on depression scales. The highest BMI values were presented in individuals with the Val allele, but the associations among $COMT$ polymorphisms and obesity were not statistically significant. The assessed population was not in Hardy–Weinberg equilibrium ($P<0.05$).

Significant interaction effects on BDI and HDRS were found for age, BMI, $DAT1$, and $COMT$. There was no significance for sex (Table 4).

Analyses of multidimensional interaction effects for BDI, HDRS, and BMI revealed significant relationships for sex, age, and both investigated polymorphisms (Table 5).

Discussion

In this study, we detected associations between $COMT$ and $DAT1$ allele polymorphisms on prevalence of depressive symptoms and intensity of BMI in obese patients. Carriers of the $COMT$ Met allele or the nine-repeat allele of $DAT1$ scored

Table 2 Effect of $DAT1$ polymorphisms on BDI, HDRS, and BMI

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>10/10 (n=167)</th>
<th>10/9 (n=175)</th>
<th>9/9 (n=22)</th>
<th>$P$-value</th>
<th>Post hoc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>101 (F)/66 (M)</td>
<td>115 (F)/60 (M)</td>
<td>15 (F)/7 (M)</td>
<td>0.5</td>
<td>No significance</td>
</tr>
<tr>
<td>Age, years</td>
<td>60.0 (21–72)</td>
<td>56.0 (20–76)</td>
<td>52.0 (23–68)</td>
<td>0.02</td>
<td>No significance</td>
</tr>
<tr>
<td>BDI</td>
<td>9 (6–18)</td>
<td>11 (5–17)</td>
<td>13 (10–20)</td>
<td>0.022</td>
<td>No significance</td>
</tr>
<tr>
<td>HDRS</td>
<td>3 (1–14)</td>
<td>4 (2–11)</td>
<td>16 (10–20)</td>
<td>0.00001</td>
<td>10/10 vs 10/9, $P=0.2$; 10/10 vs 9/9, $P=0.00006$; 10/9 vs 9/9, $P=0.000004$</td>
</tr>
<tr>
<td>BMI</td>
<td>35.2 (31.2–43.9)</td>
<td>35.3 (31.1–46.0)</td>
<td>40.1 (38.8–57.0)</td>
<td>0.001</td>
<td>10/10 vs 10/9, $P=0.07$; 10/10 vs 9/9, $P=0.002$; 10/9 vs 9/9, $P=0.03$</td>
</tr>
</tbody>
</table>

Notes: Values are expressed as the median (25%–75%). Significance of differences between genotypes was determined by Kruskal–Wallis ANOVA. Bold values indicate statistical significance.

Abbreviations: BDI, Beck Depression Inventory; HDRS, Hamilton Depression Rating Scale; BMI, body mass index; 9, nine-repeat allele; 10, ten-repeat allele; F, female; M, male; ANOVA, analysis of variance.
Table 3: Effect of COMT polymorphisms on BDI, HDRS, and BMI

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Met/Met (n=74)</th>
<th>Met/Val (n=146)</th>
<th>Val/Val (n=73)</th>
<th>P-value</th>
<th>Post hoc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>42 (F)/32 (M)</td>
<td>78 (F)/68 (M)</td>
<td>51 (F)/22 (M)</td>
<td>0.06</td>
<td>No significance</td>
</tr>
<tr>
<td>Age, years</td>
<td>56.0 (49.0–72.0)</td>
<td>45.0 (34.0–60.0)</td>
<td>62.0 (39.0–67.0)</td>
<td>0.0001</td>
<td>Met/Met vs Met/Val, ( p=0.08 )</td>
</tr>
<tr>
<td>BDI</td>
<td>13.0 (12.0–19.0)</td>
<td>9.0 (7.0–18.0)</td>
<td>9.0 (1.0–11.0)</td>
<td>0.0007</td>
<td>Met/Met vs Met/Val, ( p=0.028 )</td>
</tr>
<tr>
<td>HDRS</td>
<td>10.0 (3.0–11.0)</td>
<td>4.0 (2.0–16.0)</td>
<td>5.0 (0.0–6.0)</td>
<td>0.004</td>
<td>Met/Met vs Met/Val, ( p=0.017 )</td>
</tr>
<tr>
<td>BMI</td>
<td>34.7 (30.8–40.2)</td>
<td>36.2 (32.4–49.0)</td>
<td>35.5 (31.1–42.7)</td>
<td>0.008</td>
<td>Met/Met vs Met/Val, ( p=0.011 )</td>
</tr>
</tbody>
</table>

Notes: Values are expressed as the median (25%–75%). Significance of differences between genotypes was determined by Kruskal–Wallis ANOVA. Bold values indicate statistical significance.

Abbreviations: BDI, Beck Depression Inventory; HDRS, Hamilton Depression Rating Scale; BMI, body mass index; Met, methionine allele; Val, valine allele; F, female; M, male; ANOVA, analysis of variance.

Table 4: Analyses of unidimensional interaction effects on BDI, HDRS, and BMI

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>BDI</th>
<th>HDRS</th>
<th>BMI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SS</td>
<td>F</td>
<td>P-value</td>
</tr>
<tr>
<td>Sex</td>
<td>7.9</td>
<td>0.12</td>
<td>0.7</td>
</tr>
<tr>
<td>Age</td>
<td>2.680</td>
<td>40.3</td>
<td>0.00000001</td>
</tr>
<tr>
<td>BMI</td>
<td>1,261</td>
<td>18.9</td>
<td>0.000002</td>
</tr>
<tr>
<td>DAT1</td>
<td>707</td>
<td>5.3</td>
<td>0.005</td>
</tr>
<tr>
<td>COMT</td>
<td>899</td>
<td>6.76</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Notes: One-dimensional ANOVA F-test based on SS. Bold values indicate statistical significance.

Abbreviations: BDI, Beck Depression Inventory; HDRS, Hamilton Depression Scale; BMI, body mass index; ANOVA, analysis of variance; SS, sum of squares.
of reward region, ie, NAc, VS, and orbitofrontal cortex, to high-fat/sugar cues and also showed that regional hyperresponsiveness increased the risk for weight gain. Another study of these authors although did not present the correlation between COMT allele and the increase in BMI but suggested that greater DA capacity associated with Val allele might be connected with a future weight gain. In our study, the correlation between Val allele carriers and higher BMI values compared to Met homozygotes was presented. This might be related to greater DA capacity and hence higher dopamine signaling in such individuals. Moreover, in the study of Wallace et al, Val/Val carriers were associated with consumption of food containing high concentrations of sugar or fat, which is described as “unhealthy”. Val allele carriers present impulsivity traits that correlate with overconsumption and food additive behavior. In addition, the epistatic mechanism between COMT and DAT1 genotypes described by Hersrud and Stoltenberg might explain received results. In this study, individuals presented with Met/10 and Val/9 genotypes were associated with elevated food intake, which may lead to undesired weight changes. In our study, the highest BMI value was shown in the group of heterozygotes. However, we presume that such scores might have resulted from the presence of Val allele, which is connected with maladaptive changes in DA signaling and leads to weight gain. As we have mentioned previously, COMT is sparsely expressed in subcortical regions, and the main determinant of dopamine termination is DAT. This may explain many inconsistencies regarding the influence of COMT polymorphisms on BMI values that surely contribute to weight gain, albeit the exact mechanism is still unknown. It should be also stressed that the effect of an individual genotype may account for only a small proportion of variance in weight gain and is interdependent on other genes as well as environmental and epigenetic factors.

The mechanism leading to maladaptive changes within the reward circuit might involve changes within the dopaminergic synapse. Synaptic transmission depends on specific neurotransmitters within the synaptic cleft. The dopaminergic synapse consists of numerous elements on the pre- and postsynaptic membranes. The concentration of dopamine is dynamically regulated by various mechanisms, including pre- and postsynaptic signaling, presynaptic neurotransmitter release, and reuptake by DAT, as well as the distribution of target receptors on the pre- and postsynaptic membranes (D1 class and D2 class). Although DAT is primarily responsible for clearing excess dopamine, COMT also contributes to elimination of this neurotransmitter from the cleft.

In heterologous cell studies, Kurian et al demonstrated that DAT1 mutations responsible for the inhibition of DAT reuptake activity prolonged the presence of dopamine in the synaptic cleft, resulting in the activation of mechanisms that downregulate dopamine, ie, overstimulation of D2 autoreceptors leads to the inhibition of dopamine synthesis, increases dopamine degradation within the synaptic cleft, and eventually causes downregulation or desensitization of post-synaptic dopamine receptors. Thus, higher dopamine concentrations might contribute to lower activity of the dopaminergic system and, in this manner, cause neuropsychiatric disorders that result from dopamine depletion.

Further to this, inhibition of DAT reuptake caused by mutations was correlated with infantile parkinsonism-dystonia, a disease that arises due to dopamine deficiency. The results of that study is consistent with the results of our study and might explain the higher incidence of depressive symptoms in the nine-repeat allele carriers of DAT1.

Depressive disorder is characterized by heterogeneity of symptoms, which reflect different molecular pathologies operating in different areas of the brain. The brain’s reward areas may contribute to the manifestation of depression. The activation of VS by dopamine release prompts not only hedonism but also euphoria. Dysphoria is one of the most prominent manifestations of depressive disorders. It is presumed to be related to disturbances of dopamine signaling within the VS. Current evidence indicates that dopamine depletors and antagonists reduce motivation, lower mood, and induce a depressed state. Excessive consumption in overweight patients may cause overstimulation of dopaminergic circuits and depletion of dopamine stores in the presynaptic membrane, as well as activate secondary mechanisms due to the surfeit of dopamine within synaptic clefts.

Moreover, impairment of dopamine reuptake due to reduced DAT expression might also intensify following dopamine depletion. Eventually, this phenomenon may lead
to reduced dopaminergic stimulation, resulting in the development of dopamine deficiency with subsequent manifestation of depressive symptoms.

The association between COMT polymorphism and depressive disorders remains controversial in the literature of the field. Therefore, the Val158Met polymorphism may not be associated with susceptibility to depression, as reported by Opmeer et al. Met allele homozygotes presented with higher depressive scores in BDI and HDRS than Val homozygotes. This is consistent with other reports that the Met allele of COMT is significantly associated with vulnerability to stress and anxiety, which are major factors in the pathogenesis of depressive disorders, and therefore may be responsible for higher scores on depressive scales.\textsuperscript{11,54,55}

COMT Val158Met is associated with susceptibility to greater negative emotionality during recurrent socioemotional stress. Met allele is also suggested to interact with hypothalamic–pituitary–adrenal (HPA) axis reactivity.\textsuperscript{56} HPA, which is responsible for the stress transmission, is considered to play a key role in the pathogenesis of obesity and depression. An inflammatory cytokine IL-6 activates HPA axis and is involved in both obesity and depression, which are considered to show dysregulation of HPA axis.\textsuperscript{57,58} What are the effects of stressors on the dopamine system? It depends on the duration of their impact. Obesity may be seen as the chronic inflammatory state.\textsuperscript{58} Chronic stressors affect DA system by stress-induced activation of VTA, following down-regulation of neuron firing in this region, which may project to other reward-related areas. Unlike to acute stress stimuli, such condition lasts longer. This turn of events may lead to depressive symptoms such as anhedonia or amotivation. Evidence indicates that disruption in the DA system resulting in deficits in frontal cortical regions, involving reward regions, contributes to the pathogenesis of depression.\textsuperscript{13}

This process elucidates the COMT contribution in the development of depression and shows the interplay between obesity and the neuropsychiatric disorders in their pathogenesis.

The association between depressive disorders and obesity has been reported in multiple studies; however, the responsible neurobiological mechanism remains unknown. ANOVA revealed a correlation between obesity and the intensity of subjective depressive symptoms in HDRS but not in BDI. Lasserre et al\textsuperscript{59} suggested that heterogeneity of depressive symptoms may explain the contradictory findings of comorbidity between depression and obesity and pointed out that depression with atypical features (eg, elevated appetite, emotional eating, and poor physical activity) is associated with increased adiposity as determined by BMI. Numerous studies reveal a positive association between atypical depression and higher BMI. The adiposity rates of those participants are significantly greater than those individuals who have never been depressed or who present with another subtype of depression.\textsuperscript{60–63} Such findings imply high comorbidity between atypical depression and adiposity and advocate to subtype depression diagnosis in future research because the atypical subtype of depression might be a strong predictor of adiposity.\textsuperscript{59}

**Conclusion**

We found that polymorphisms of the DAT1 and COMT genes, which are involved in dopaminergic neurotransmission, were associated with a higher intensity of depressive symptoms in obese population. Individuals with the DAT1 nine-repeat allele or homozygotes of the COMT Met allele manifested more severe depressive symptoms in BDI and HDRS. Homozygotes for the DAT1 nine-repeat allele presented the highest BMI values in obese populations, indicating that the DAT1 VNTR polymorphism was significantly associated with severity of obesity. Likewise, the COMT Val158Met polymorphism was connected with BMI values, and Val/Met carriers presented the highest adiposity concentration on the contrary to Met homozygotes. Our results indicate that maladaptive changes within the reward system could increase susceptibility to depressive and eating disorders due to alterations in dopaminergic neurotransmission.

**Acknowledgment**

This research was supported by a grant from the Polish Ministry of Science and Higher Education (Grant No NN 402053136).

**Author contributions**

A Borkowska, R Junik, and A Tretyn conceived the idea for the study. M Bieliński and M Jaracz contributed to the design of the research. M Bieliński, M Jaracz, N Lesiewska, M Tomaszewska, and A Kamińska were involved in data collection. M Bieliński, M Jaracz, N Lesiewska, and A Borkowska analyzed the data. M Bieliński and N Lesiewska wrote the manuscript. A Borkowska coordinated funding for the project. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.
References


